Related references
Note: Only part of the references are listed.E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function
Tanis D. Godwin et al.
GASTRIC CANCER (2019)
Hereditary gastric cancer: what's new? Update 2013-2018
Rachel S. van der Post et al.
FAMILIAL CANCER (2019)
Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome
Kim M. Keppler-Noreuil et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2019)
E-cadherin: Its dysregulation in carcinogenesis and clinical implications
Sonia How Ming Wong et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials
Xuan Li et al.
PLOS ONE (2018)
A proteomic landscape of diffuse-type gastric cancer
Sai Ge et al.
NATURE COMMUNICATIONS (2018)
Maximising the potential of MKT inhibitors as anti-cancer treatments
Jessica S. Brown et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer
Sharon Pattison et al.
PLOS ONE (2017)
Results of a phase Ib study of ARQ 092 in combination with carboplatin (C) plus paclitaxel (P), or with P in patients (pts) with solid tumors.
Nehal Lakhani et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use
George Mihai Nitulescu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Three-Dimensional Gastrointestinal Organoid Culture in Combination with Nerves or Fibroblasts: A Method to Characterize the Gastrointestinal Stem Cell Niche
Agnieszka Pastula et al.
STEM CELLS INTERNATIONAL (2016)
A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC).
A. Dasari et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)
Ramesh K. Ramanathan et al.
CANCER (2015)
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Joan Montero et al.
CELL (2015)
Results from a phase 1 study of ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma
A. Tolcher et al.
EUROPEAN JOURNAL OF CANCER (2015)
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers
Rachel S. van der Post et al.
JOURNAL OF MEDICAL GENETICS (2015)
SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer
Ana M. Gonzalez-Angulo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine
Jeng-Wei Lu et al.
MEDICAL ONCOLOGY (2015)
Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells
Bryony J. Telford et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome
Marjorie J. Lindhurst et al.
SCIENTIFIC REPORTS (2015)
SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer
Ana M. Gonzalez-Angulo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Hereditary Diffuse Gastric Cancer Syndrome CDH1 Mutations and Beyond
Samantha Hansford et al.
JAMA ONCOLOGY (2015)
A Comparison of Real-Time and Endpoint Cell Viability Assays for Improved Synthetic Lethal Drug Validation
Andrew Single et al.
JOURNAL OF BIOMOLECULAR SCREENING (2015)
E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition
Augustine Chen et al.
BMC CANCER (2014)
E-Cadherin Couples Death Receptors to the Cytoskeleton to Regulate Apoptosis
Min Lu et al.
MOLECULAR CELL (2014)
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Charity W. Law et al.
GENOME BIOLOGY (2014)
BH3 profiling in whole cells by fluorimeter or FACS
Jeremy Ryan et al.
METHODS (2013)
Epithelial-mesenchymal transition mediates anoikis resistance and enhances invasion in pleural effusion-derived human lung cancer cells
Preedakorn Chunhacha et al.
ONCOLOGY LETTERS (2013)
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
Clifford Hudis et al.
BREAST CANCER RESEARCH (2013)
Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
James F. Blake et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis
Yan Cheng et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Novel Inhibitors of AKT: Assessment of a Different Approach Targeting the Pleckstrin Homology Domain
E. J. Meuillet
CURRENT MEDICINAL CHEMISTRY (2011)
Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination
Hakryul Jo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor
Emmanuelle J. Meuillet et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
Wen-I Wu et al.
PLOS ONE (2010)
Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes
Jeremy A. Ryan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Methodological approaches in application of synthetic lethality screening towards anticancer therapy
D. Canaani
BRITISH JOURNAL OF CANCER (2009)
Inhibitor hijacking of Akt activation
Tatsuya Okuzumi et al.
NATURE CHEMICAL BIOLOGY (2009)
The cell-cell adhesion molecule E-cadherin
F. van Roy et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
Activated Akt as an indicator of prognosis in gastric cancer
Caterina Cinti et al.
VIRCHOWS ARCHIV (2008)
Formation of E-cadherin-mediated cell-cell adhesion activates Akt and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells
P Reddy et al.
MOLECULAR ENDOCRINOLOGY (2005)
PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury
T Nagoshi et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Share Paper
